BridgeBio Pharma, Inc. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent
BridgeBio Pharma, Inc. (BBIO) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent of 4.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent · last filed 2026-02-24
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2025 was 4.20%, a 200.00% increase from fiscal 2024.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2024 was 1.40%, a 180.00% increase from fiscal 2023.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2023 was 0.50%.
- BridgeBio Pharma, Inc. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, percent for fiscal 2022 was -1.80%, a 250.00% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 4.20% 10-K · filed 2026-02-24 | |
| 2024-12-31 | 1.40% 10-K · filed 2026-02-24 | 1.30% 10-K · filed 2025-02-20 |
| 2023-12-31 | 0.50% 10-K · filed 2026-02-24 | 0.60% 10-K · filed 2024-02-22 |
| 2022-12-31 | -1.80% 10-K · filed 2025-02-20 | |
| 2021-12-31 | 1.20% 10-K · filed 2024-02-22 | |
| 2020-12-31 | 1.00% 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |